209 related articles for article (PubMed ID: 35766058)
1. Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland.
Brola W; Adamczyk-Sowa M; Kułakowska A; Głażewska J; Smaga A; Bartosik-Psujek H
Neurol Neurochir Pol; 2022; 56(3):256-260. PubMed ID: 35766058
[TBL] [Abstract][Full Text] [Related]
2. Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland.
Kapica-Topczewska K; Collin F; Tarasiuk J; Chorąży M; Czarnowska A; Kwaśniewski M; Brola W; Bartosik-Psujek H; Adamczyk-Sowa M; Kochanowicz J; Kułakowska A
Neurol Neurochir Pol; 2020; 54(2):161-168. PubMed ID: 32219813
[TBL] [Abstract][Full Text] [Related]
3. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
4. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
Iaffaldano P; Lucisano G; Guerra T; Patti F; Cocco E; De Luca G; Brescia Morra V; Pozzilli C; Zaffaroni M; Ferraro D; Gasperini C; Salemi G; Bergamaschi R; Lus G; Inglese M; Romano S; Bellantonio P; Di Monte E; Maniscalco GT; Conte A; Lugaresi A; Vianello M; Torri Clerici VLA; Di Sapio A; Pesci I; Granella F; Totaro R; Marfia GA; Danni MC; Cavalla P; Valentino P; Aguglia U; Montepietra S; Ferraro E; Protti A; Spitaleri D; Avolio C; De Riz M; Maimone D; Cavaletti G; Gazzola P; Tedeschi G; Sessa M; Rovaris M; Di Palma F; Gatto M; Cargnelutti D; De Robertis F; Logullo FO; Rini A; Meucci G; Ardito B; Banfi P; Nasuelli D; Paolicelli D; Rocca MA; Portaccio E; Chisari CG; Fenu G; Onofrj M; Carotenuto A; Ruggieri S; Tortorella C; Ragonese P; Nica M; Amato MP; Filippi M; Trojano M;
J Neurol; 2024 Mar; 271(3):1150-1159. PubMed ID: 38135850
[TBL] [Abstract][Full Text] [Related]
9. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
10. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.
Sippel A; Riemann-Lorenz K; Scheiderbauer J; Kleiter I; Morrison R; Kofahl C; Heesen C
BMC Health Serv Res; 2021 Oct; 21(1):1141. PubMed ID: 34686166
[TBL] [Abstract][Full Text] [Related]
11. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
12. Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Müller J; Roos I; Kalincik T; Lorscheider J; Galli E; Benkert P; Schädelin S; Sharmin S; Einsiedler M; Hänni P; Schmid J; Kuhle J; Derfuss T; Granziera C; Ziemssen T; Siepmann T; Yaldizli Ö
Brain Behav; 2024 May; 14(5):e3498. PubMed ID: 38688877
[TBL] [Abstract][Full Text] [Related]
13. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
[TBL] [Abstract][Full Text] [Related]
14. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
15. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
16. The association between deprivation and the access to disease modifying therapies for multiple sclerosis: An England wide community-based study in the UK MS Register.
Das J; Rog DJ; Middleton R; Rodgers JW; Fry R; Nicholas R
Mult Scler Relat Disord; 2022 Jan; 57():103474. PubMed ID: 34986456
[TBL] [Abstract][Full Text] [Related]
17. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
[TBL] [Abstract][Full Text] [Related]
18. Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional study.
Finkener S; Achtnichts L; Cervenakova M; Nedeltchev K; Findling O
Mult Scler Relat Disord; 2022 Dec; 68():104396. PubMed ID: 36544325
[TBL] [Abstract][Full Text] [Related]
19. Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care.
Ozen NPA; Dursun EG; Tuncer A; Karabudak R
Mult Scler Relat Disord; 2024 Apr; 84():105503. PubMed ID: 38422633
[TBL] [Abstract][Full Text] [Related]
20. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
Zafar A; AlShamrani FJG
Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
